3 Dividend-Paying Drug Stocks to Buy at a Discount

The article analyzes the dividend yields and risk profiles of pharmaceutical giants Pfizer, Bristol Myers Squibb (BMS), and Merck for institutional investors. Pfizer offers a 7% yield but faces high dividend cut risk due to a 90% payout ratio, a history of past cuts, and recent acquisitions like Metsera, positioning it as a value or turnaround play. BMS, with a 5.6% yield and a 99% payout ratio, is actively acquiring to mitigate upcoming patent cliffs, presenting moderate dividend risk despite a lack of recent cuts. Merck, however, provides a lower 3.7% yield but features a more sustainable 50% payout ratio and favorable valuation metrics, indicating minimal dividend cut risk and making it the most secure option for risk-averse income investors.

Analysis

The analysis highlights the varying risk-reward profiles among pharmaceutical giants Pfizer, Bristol Myers Squibb (BMY), and Merck, particularly concerning their dividend sustainability amidst patent cliffs and M&A activities. Pfizer offers a substantial 7% dividend yield, significantly above the market average, but this is coupled with a high 90% trailing-12-month payout ratio and a history of dividend cuts, notably in 2009. Its recent $4.9 billion Metsera acquisition, while pipeline-bolstering, exacerbates concerns regarding dividend safety, positioning it more as a value or turnaround play given its below five-year average P/S, P/E, and P/B ratios.

Bristol Myers Squibb presents a 5.6% yield with an even higher 99% payout ratio, indicating significant pressure on its dividend despite 19 years of increases and no cuts in three decades. The company has aggressively pursued M&A in 2024, acquiring Mirati Therapeutics, RayzeBio, and Karuna Therapeutics, to mitigate upcoming patent losses starting next year. While its historical dividend resilience is noted, the extremely high payout ratio and looming patent expirations suggest moderate dividend risk.

In contrast, Merck offers a lower 3.7% yield but boasts a more sustainable 50% payout ratio, providing substantial buffer against adversity. Despite anticipated patent cliffs in 2029 and 2030, Merck's robust pipeline and strategies to protect Keytruda's patent position it favorably. Its valuation metrics (P/S, P/E, P/B) are all below their five-year averages, reinforcing a more attractive risk-reward profile with minimal dividend cut risk, making it a more secure option for risk-averse income investors.

Key Decisions for Investors

• Investors seeking high dividend yields from Pfizer and Bristol Myers Squibb should carefully assess the elevated risk of dividend cuts due to their high payout ratios and the integration challenges of recent M&A activities.
• Consider Merck for a more secure, albeit lower, dividend income stream, given its sustainable 50% payout ratio and favorable valuation metrics, making it suitable for risk-averse income investors.
• Monitor the success of pipeline development and M&A integration for Pfizer and Bristol Myers Squibb, as these factors are critical for mitigating patent cliff impacts and supporting future dividend stability.